5 out of 10 concussions go undiagnosed in youth sports

Neurolytixs has leveraged artificial intelligence to diagnose concussions with blood biomarkers within 48 hours of an incident

67 Yonge Street, Suite 701. Toronto, ON. Canada.

Pricing

DEVELOPED IN PARTNERSHIP WITH

Product analytics answers your questions

Maecenas varius nunc a odio ultrices, non consectetur nunc scelerisque. Mauris nec condimentum est, id eleifend orci.

Better understand you customers

Explain the features and what it acompolishes. What does your company offer that will improve or solve a problem?

Toronto

© 2020 Neurolytixs Inc All rights reserved

ABOUT US

Neurolytixs leverages artificial intelligence to easily, quickly and precisely diagnose concussions with 96% accuracy within 48 hours of an incident using a finger prick

BRAIN HEALTH FOR THE NEXT GENERATION

Improve acquisition

Lacinia condimentum lectus dolor viverra nunc. Mauris quis condimentum orci. Curabitur hendrerit, felis vitae.

Drive customer retention

Curabitur quis purus congue ante interdum mattis sit amet at ante. Nulla volutpat, magna quis convallis tristique.

Between 1.7 and 3 million sports and recreation related concussions happen each year in the US

2 in 10 high-school athletes who play contact sports will suffer a concussion this year

Girls' soccer sees the second-most concussions of all high school sports

Incident Test

Shipping to a Neurolytixs laboratory

 

Incident test using a finger prick

Preventive removal from play after incident 

Analysis

Baseline Test

Baseline test using a finger prick

Shipping to a Neurolytixs laboratory

Secure storage

Currently, concussions are diagnosed subjectively through physical, cognitive, and behavioural methodologies – threatening the long-term brain health of Canadian youth, athletes, and military personnel.

Source: UPMC Sports Medicine

The Science

Neurolytixs’ ground-breaking technology is revolutionizing concussion diagnosis. Our proprietary research has identified a number of blood biomarkers that accurately identify brain injury among patients. Developed by Dr. Doug Fraser, a professor, clinician scientist, and Fellow of the Royal College of Physicians and Surgeons of Canada, this technology is the first test of its kind to yield up to 96% accuracy in concussion diagnosis.

DISCLAIMER: Neurolytixs is based on research to date and has not been reviewed by FDA or Health Canada. At the moment, Neurolytixs is an R&D company and is not to be used for concussion diagnosis

WATCH VIDEORead team bios

Toronto

67 Yonge Street, Suite 701. Toronto, ON. Canada.

ABOUT US

Neurolytixs has leveraged artificial intelligence to diagnose concussions with blood biomarkers test with within 48 hours of an incident

© 2020 Neurolytixs Inc All rights reserved

The Team

Get Involved

Dr. Douglas Fraser, MD, PhD
Chief Medical Officer

Peter George
Chief Executive Officer

Adrian Uthay
Chief Financial Officer

The Problem

Dr. Alicia DiBattista
Chief Technology Officer

PatentsNewsScienceAbout UsHome